Table 3.
Comparison of Diagnostic Accuracy of ElastPQ and TE for Detecting Any Fibrosis, Significant Fibrosis, and Advanced Fibrosis in Total Group Fibrosis at Optimal Cutoff (kPa) Values.
| Modality | Optimal cutoff (kPa) | AUROC | Std. error | 95% CI | Difference between areas | Std. error | 95% CI | P-value |
|---|---|---|---|---|---|---|---|---|
| Any fibrosis (F > 1) | ||||||||
| ElastPQ | 5.37 | 0.907 | 0.0524 | 0.751 to 0.980 | 0.0364 | 0.0587 | −0.0788 to 0.151 | 0.536 |
| TE | 6.0 | 0.870 | 0.0648 | 0.704 to 0.962 | ||||
| Significant fibrosis (F > 2) | ||||||||
| ElastPQ | 5.96 | 0.959 | 0.0344 | 0.823 to 0.998 | 0.189 | 0.0775 | 0.0367 to 0.341 | 0.015 |
| TE | 8.8 | 0.770 | 0.0858 | 0.588 to 0.900 | ||||
| Advanced fibrosis (F > 3) | ||||||||
| ElastPQ | 8.42 | 0.926 | 0.0623 | 0.776 to 0.998 | 0.0444 | 0.0425 | −0.0388 to 0.128 | 0.295 |
| TE | 11.2 | 0.881 | 0.0863 | 0.718 to 0.968 | ||||
| CVH | ||||||||
| Any fibrosis (F > 1) | ||||||||
| ElastPQ | 5.37 | 0.955 | 0.0525 | 0.710 to 1.000 | 0.0227 | 0.0321 | −0.0403to 0.0857 | 0.480 |
| TE | 5.8 | 0.932 | 0.0719 | 0.678 to 0.998 | ||||
| Significant fibrosis (F > 2) | ||||||||
| ElastPQ | 5.96 | 0.861 | 0.103 | 0.589 to 0.982 | 0.333 | 0.162 | 0.0167 to 0.650 | 0.039 |
| TE | 5.8 | 0.528 | 0.150 | 0.261 to 0.783 | ||||
| CVH without ESRD | ||||||||
| Any fibrosis (F > 1) | ||||||||
| ElastPQ | 5.57 | 0.833 | 0.192 | 0.397 to 0.993 | 0.0833 | 0.118 | −0.148to 0.314 | 0.480 |
| TE | 5.8 | 0.750 | 0.264 | 0.321 to 0.975 | ||||
| NAFLD | ||||||||
| Any fibrosis (F > 1) | ||||||||
| ElastPQ | 5.02 | 0.902 | 0.0762 | 0.660 to 0.991 | 0.0455 | 0.1020 | −0.154to 0.245 | 0.655 |
| TE | 8.8 | 0.856 | 0.0958 | 0.604 to 0.976 | ||||
| Significant fibrosis (F > 2) | ||||||||
| ElastPQ | 5.87 | 1.00 | 0.000 | 0.805 to 1.000 | 0.0643 | 0.0563 | −0.0461to 0.175 | 0.254 |
| TE | 10.2 | 0.936 | 0.0563 | 0.705 to 0.998 | ||||
| Advanced fibrosis (F > 3) | ||||||||
| ElastPQ | 8.04 | 0.981 | 0.0272 | 0.772 to 1.000 | 0.0192 | 0.0272 | −0.0341 to 0.0725 | 0.480 |
| TE | 11.2 | 1.000 | 0.000 | 0.805 to 1.000 | ||||
| NAFLD with inactive HBsAg | ||||||||
| Any fibrosis (F > 1) | ||||||||
| ElastPQ | 5.79 | 1.000 | 0.000 | 0.541 to 1.000 | 0.000 | 0.000 | 0.000 | 1.00 |
| TE | 9.0 | 1.000 | 0.000 | 0.541 to 1.000 | ||||
| Significant fibrosis (F > 2) | ||||||||
| ElastPQ | 5.79 | 1.000 | 0.000 | 0.541 to 1.000 | 0.000 | 0.000 | 0.000 | 1.00 |
| TE | 9.0 | 1.000 | 0.000 | 0.541 to 1.000 | ||||
| NAFLD without inactive HBsAg | ||||||||
| Any fibrosis (F > 1) | ||||||||
| ElastPQ | 4.62 | 0.944 | 0.0786 | 0.633 to 1.000 | 0.167 | 0.290 | −0.402 to 0.735 | 0.566 |
| TE | 4.4 | 0.778 | 0.239 | 0.440 to 0.962 | ||||
| Significant fibrosis (F > 2) | ||||||||
| ElastPQ | 6.04 | 1.000 | 0.000 | 0.715 to 1.000 | 0.100 | 0.110 | −0.115 to 0.315 | 0.361 |
| TE | 10.2 | 0.900 | 0.110 | 0.576 to 0.997 | ||||
| Advanced fibrosis (F > 3) | ||||||||
| ElastPQ | 8.04 | 0.958 | 0.0589 | 0.652 to 1.000 | 0.0417 | 0.0589 | −0.0738 to 0.157 | 0.480 |
| TE | 11.2 | 1.000 | 0.000 | 0.715 to 1.000 | ||||
CVH, chronic viral hepatitis; NAFLD, nonalcoholic fatty liver disease; ESRD, end-stage renal disease; ElastPQ, elastography point quantification; AUROC; area under the receiver operating characteristic; TE, transient elastography.